%PDF-1.3
%ºß¬à
3 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 4 0 R
>>
endobj
4 0 obj
<<
/Length 4010
>>
stream
0.5670000000000001 w
0 G
BT
/F1 16 Tf
18.3999999999999986 TL
0 g
113.4799999999998903 771.0238582677164914 Td
(United Therapeutics Corporation Q1 2025 Transcript) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 714.3309448818897636 Td
(Good morning and welcome to the United Therapeutics Corporation First Quarter) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today.) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(All participants on the call portion of this webcast will be in listen-only mode until the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(question-and-answer portion of this earnings call. [Operator Instructions] Please note, this call) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 600.9451181102361943 Td
(is being recorded. I would now like to turn the webcast over to Dewey Steadman, Head of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 572.5986614173227736 Td
(Investor Relations at United Therapeutics.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 530.0789763779526993 Td
(Please go ahead. ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 487.559291338582625 Td
(Dewey Steadman: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.7661417322834438 487.559291338582625 Td
(Thank you Dorwin [ph] and good morning. It is my pleasure to welcome you) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 459.2128346456692611 Td
(to the United Therapeutics Corporation first quarter 2025 corporate update webcast. Remarks) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(today will include forward-looking statements representing our expectations or beliefs) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(regarding future events. These statements involve risks and uncertainties that may cause) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(contain additional information on these risks and uncertainties and we assume no obligation to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(update these forward-looking statements.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 274.9608661417322537 Td
(Dewey Steadman: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.7661417322834438 274.9608661417322537 Td
(Today's remarks may discuss the progress and results of clinical trials or) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 246.614409448818833 Td
(other developments with respect to our products. These remarks are intended solely to educate) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(investors and are not intended to serve as the basis for medical decision-making or to suggest) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(that any products are safe and effective for any unapproved or investigational uses. Full) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(prescribing information for those products are available on our website. Companying me on) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 76.5356692913385359 Td
(Officer and Treasurer; Dr. Leigh Peterson, our Executive Vice President of Product) Tj
ET
endstream
endobj
5 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 6 0 R
>>
endobj
6 0 obj
<<
/Length 4030
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(Development and Xenotransplantation; and Pat Poisson, our Executive Vice President of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(Technical Operations.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 700.15771653543311 Td
(Dewey Steadman: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.7661417322834438 700.15771653543311 Td
(Our scientific, commercial and medical affairs team will present at the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 671.8112598425196893 Td
(American Thoracic Society International Conference in San Francisco from May 16 to the 21st.) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(And now I will turn the webcast over for Martine for an overview of our development pipeline) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 615.1183464566928478 Td
(and business activities. Martine?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 572.5986614173227736 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 572.5986614173227736 Td
(Thank you Dewey and good morning everyone. We have slides available for) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 544.2522047244094665 Td
(reference and I encourage you to review those at your leisure. However, Mike and I will not) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 515.9057480314959321 Td
(speak directly to the slides. How often can a CEO report to their investors and stakeholders) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 487.559291338582625 Td
(that we've had a record revenue quarter. For United Therapeutics, it has been 9 quarters out of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 459.2128346456692611 Td
(the past 12. That reflects on the strong execution of our long-term vision to be a biotech leader) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(with a relentless drive to deliver to patients with rare and underserved diseases, a broad array) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(of solutions to help improve their lives.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 360.0002362204724022 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 360.0002362204724022 Td
(Our solid foundation built by Tyvaso, Orenitram, Remodulin and Unituxin) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 331.6537795275589815 Td
(continues to grow revenue by double digits now for 11 quarters in a row. We expect this) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 303.3073228346455608 Td
(momentum to continue, led by Tyvaso and Tyvaso DPI with continued solid performance by) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 274.9608661417322537 Td
(our other commercial products. Moving to our innovation and revolution waves. We believe our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 246.614409448818833 Td
(record revenue performance can continue for the foreseeable future as we have entered a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(sustained period of clinical and regulatory events poised to propel our business forward.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 175.748267716535338 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 175.748267716535338 Td
(We continue to grow our pipeline with 5 registration phase studies) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 147.4018110236219172 Td
(underway, a pending marketing application at the FDA and several new preclinical candidates,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 119.0553543307086102 Td
(including 3 xeno organs that should be ready for clinical trials within a year. We also have) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 90.7088976377951894 Td
(other exciting innovations we will share later that we expect will keep our product portfolio) Tj
ET
endstream
endobj
7 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 8 0 R
>>
endobj
8 0 obj
<<
/Length 4147
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(innovating for years to come. We're planning for the first transplant in our UKidney clinical) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(study which we're calling the EXPAND study in the middle of this year. This will be followed by) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(investigational new drug applications for the EXTEND study evaluating the UTHYMOKIDNEY) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(and the EXPRESS study evaluating the UHeart.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 643.4648031496062686 Td
(Both of those INDs are expected to be submitted within the next year. We) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 615.1183464566928478 Td
(recently received positive feedback from the FDA on our UTHYMOKIDNEY program that gives) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(us confidence to file INDs for both the UTHYMOKIDNEY and UHeart without conducting) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(additional Baboon clinical studies. What makes United Therapeutics unlike any other biotech is) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(that we've been able to accomplish this massive business growth and unparalleled pipeline) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(productivity while maintaining strict financial discipline. We never spent more than 50% of prior) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(year revenue on cash operating expenses.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 430.8663779527558404 Td
(And as a result, we have an industry-leading productivity per employee and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(more than $1 billion in annual operating cash flow. And we're deploying our capital) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(thoughtfully and strategically to provide for a sustainable business in the years to come. In the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(past 6 quarters, we have touched on all 3 areas of our capital allocation philosophy across both) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(our commercial and development portfolios. We've invested in CapEx to support our new) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(Tyvaso DPI manufacturing facility and acquired additional real estate to support future) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(commercial manufacturing needs.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 218.2679527559054122 Td
(We also commissioned the world's first clinical scale designated) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(pathogen-free facility in Virginia and plan to complete 2 others in short order. On corporate) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(development, we acquired IVIVA and Miromatrix to enhance our organ alternative development) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(expertise and we've licensed in new technologies to support our small molecule business. And) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(with all this, we still returned $1 billion to you, our shareholders, through an accelerated share) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 76.5356692913385359 Td
(repurchase program last year that was universally well received. We will continue to evaluate) Tj
ET
endstream
endobj
9 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 10 0 R
>>
endobj
10 0 obj
<<
/Length 3953
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(all 3 core areas of our capital allocation philosophy on an ongoing basis and we plan to pursue) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(multiple avenues of capital allocation in the future.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 700.15771653543311 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 700.15771653543311 Td
(Our commercial business is extremely strong and growing. That, along with) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 671.8112598425196893 Td
(5 registration studies underway, several important data reads in the next 18 months and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(revolutionary progress on revolutionary organ programs makes United Therapeutics a truly) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 615.1183464566928478 Td
(unique and compelling story. And I thank you, our stakeholders and shareholders for joining us) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(on this journey. We're only just beginning. And with that, I'll now turn the call over to our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(President, Mike Benkowitz, who will give an overview of our spectacular commercial) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(performance for the quarter.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 487.559291338582625 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 487.559291338582625 Td
(Mike? ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 445.0396062992125508 Td
(Thank you Martine and good morning everyone. Today we are pleased to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 416.69314960629913 Td
(report a strong start to the year with another quarter of record revenue at $794 million,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 388.3466929133857661 Td
(representing 17% growth from the first quarter of 2024. driven by robust results for each of our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 360.0002362204724022 Td
(treprostinil products. This quarter's performance is reflective of consistent patient demand) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 331.6537795275589815 Td
(where we continue to see very strong referrals, starts and patient shipments for all of our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 303.3073228346455608 Td
(treprostinil products, Tyvaso, both DPI and nebulizer, Orenitram and Remodulin as well as) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 274.9608661417322537 Td
(Unituxin.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 232.4411811023621794 Td
(We continue to see growth in the number of treprostinil prescribers and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 204.0947244094487587 Td
(increases in the depth of prescribing within practices as measured by writers with 3 or more) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 175.748267716535338 Td
(patients. Overall, we believe these results demonstrate that treprostinil continues to be an) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 147.4018110236219172 Td
(important part of the treatment armamentarium for pulmonary hypertension even with new) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 119.0553543307086102 Td
(therapies reaching the market. Building on Martine's comments, we remain confident that) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 90.7088976377951894 Td
(Tyvaso DPI is positioned for sustained growth over the long term due to the convenience of the) Tj
ET
endstream
endobj
11 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 12 0 R
>>
endobj
12 0 obj
<<
/Length 3794
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(device, its unlimited dosing potential, the thousands of prescribers and many, many thousands) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(of patients experienced with the product since launch as well as the fact that there are no payer) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(incentives to prefer an alternative product. Moreover, if positive, the TETON data in idiopathic) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(pulmonary fibrosis which is expected soon, could shift Tyvaso use into a much larger market) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(where we will have orphan drug exclusivity and rapidly position Tyvaso for continued) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(long-term growth.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 586.7718897637794271 Td
(To wrap up, we couldn't be prouder of the unwavering effort of our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(dedicated team to deliver this outstanding performance and to provide therapies to our patients) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(in need. And we believe that we are set up well to continue to execute throughout the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(remainder of the year and beyond. With that, I'll turn things back to Martine to run the Q&A) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(session.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 430.8663779527558404 Td
(Thank you so much, Mike. That's an amazing report. Operator, can we have) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(the first caller, please?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 360.0002362204724022 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 360.0002362204724022 Td
([Operator Instructions] The first question comes from Joseph Thome with TD Cowen.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(Joseph Thome: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
146.2661417322834723 317.480551181102328 Td
(On the quarter. Maybe will the UTHYMOKIDNEY program enroll the same target) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(population as the 10-gene kidney program? And we saw the great progress, obviously, with Ms.) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(Looney but then I did see that she did have to be explanted. So maybe if you could talk a little) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(bit about what you learned from that experience and how you might apply that to the upcoming) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 204.0947244094487587 Td
(trial, that would be great.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 161.5750393700786844 Td
(Sure. Thank you for your question, Joe and thank you for the congrats. I'm) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(going to assign that question to Dr. Leigh Peterson. She's in charge of all of our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(xenotransplantation activities. Dr. Peterson?) Tj
ET
endstream
endobj
13 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 14 0 R
>>
endobj
14 0 obj
<<
/Length 4092
>>
stream
0.5670000000000001 w
0 G
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(Leigh Peterson: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
148.8661417322834666 771.0238582677164914 Td
(Yes. Thanks for the call. And yes, we haven't completed our clinical protocol) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(for our UTHYMOKIDNEY study yet. But yes, we do plan on enrolling a very similar, if not) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(identical patient population into that study as what we're enrolling into the 10-gene xenokidney) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(study. And yes, we learned an incredible amount. We're very, very grateful for Ms. Looney's) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(participation through the EIND conducted by NYU. And we learned a lot.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 615.1183464566928478 Td
(Leigh Peterson: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
148.8661417322834666 615.1183464566928478 Td
(We learned a little bit more about tweaking the immunosuppression which is a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(little bit different than what's commonly done in allo transplantation. And we're looking forward) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(to applying all of the learnings with regard to the immunosuppression and follow-up that we) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(learned with her. So again, we're really, really grateful. We consider it definitely a positive) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(experience and it's unfortunate that she did have the unrelated infection that required us to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(have to reduce the amount of immunosuppression that she was on which ultimately resulted in) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(rejection.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(Leigh Peterson: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
148.8661417322834666 402.5199212598424765 Td
(But again, it was an unrelated infection. And so learning how to manage that) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(without having to reduce the immunosuppression quite as much is going to be key in the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(study.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 303.3073228346455608 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 303.3073228346455608 Td
(Thank you so much, Dr. Peterson, for all of that great color on the progress) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 274.9608661417322537 Td
(that we're making both with the 10-gene kidney and with the UTHYMOKIDNEY and the -- and as) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 246.614409448818833 Td
(we are now referring to the trials as the EXPAND trial for the 10-gene kidney which is now) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(enrolling.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 175.748267716535338 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 175.748267716535338 Td
(Our next question is from Jessica Fye with JPMorgan. ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(Jessica Fye: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
132.6661417322834779 133.2285826771652637 Td
(Congrats on the strong quarter. I was wondering if you could elaborate for Tyvaso) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(on kind of the magnitude of year-over-year contribution to sales from the continued) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 76.5356692913385359 Td
(implementation of the Part D redesign. I think you guys had previously said that was kind of) Tj
ET
endstream
endobj
15 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 16 0 R
>>
endobj
16 0 obj
<<
/Length 3944
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(mostly realized in '24. So I'm just curious the extent to which you're seeing that benefit again) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(this year as the out-of-pocket cap is further reduced.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 700.15771653543311 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 700.15771653543311 Td
(Yes. Thank you so much for that question and so nice to hear your voice this) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 671.8112598425196893 Td
(morning. If it's okay with you, I think the best person to address that question would be Michael) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(Benkowitz. Mike?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 600.9451181102361943 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 600.9451181102361943 Td
(Yes. Thanks, Martine. Thanks, Jess, for the question. Yes, I think if you're) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 572.5986614173227736 Td
(looking year-over-year, so Q1 of this year to Q1 last year, I mean, there's obviously a benefit,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 544.2522047244094665 Td
(right? And I think we've talked about the last quarter. So we saw a step down in Q1 last year,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 515.9057480314959321 Td
(continue to kind of step down into Q2 and Q3 and then kind of flatten out over the balance of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 487.559291338582625 Td
(the year. If I look at Q1 versus Q4, I would say like a modest benefit but then I think you also) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 459.2128346456692611 Td
(have to kind of counter -- on the flip side of that is with the manufacturers having to start to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(pick up part of the catastrophic on the back end of the Part D redesign, we had some) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(obligations there.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 360.0002362204724022 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 360.0002362204724022 Td
(Obviously, it was less because we have the phase-in. So I think -- I haven't) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 331.6537795275589815 Td
(looked at the math to see if those exactly cancel each other out. But I think by and large, they) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 303.3073228346455608 Td
(probably do. So I think any benefit is really, I think, very, very modest when looking at the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 274.9608661417322537 Td
(results this quarter.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 232.4411811023621794 Td
(Great answer, Mike. fully nailed it and that queues us up for our next) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 204.0947244094487587 Td
(questioner. Operator, you can open up the line.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 161.5750393700786844 Td
(Yes. We have Roanna Ruiz with Leerink Partners with the next question. ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 119.0553543307086102 Td
(Roanna Ruiz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
137.366141732283495 119.0553543307086102 Td
(So I was going to ask about Tyvaso DPI revenue growth specifically in 1Q. Could) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 90.7088976377951894 Td
(you help us understand just the general split of prescriber and patient demand driving growth) Tj
ET
endstream
endobj
17 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 18 0 R
>>
endobj
18 0 obj
<<
/Length 4018
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(versus a little bit of price increase? And are there any gross to net impacts that we should think) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(about for the product in 1Q or going forward?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 700.15771653543311 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 700.15771653543311 Td
(Yes. Thanks, Roanna. Michael, again, would be totally on top of all of those) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 671.8112598425196893 Td
(numbers. So Mike, can you take that call?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 629.291574803149615 Td
(Sure. Yes. So I think in terms of split between DPI and nebulizer, I think it's) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 600.9451181102361943 Td
(settled in at about 2/3, 1/3 in terms of new patient starts. We haven't really seen much variability) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 572.5986614173227736 Td
(from that really for several quarters now. So I think that mix persists. And it's great that we) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 544.2522047244094665 Td
(have both options, right? Because there just happen to be patients that tolerate a nebulizer) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 515.9057480314959321 Td
(better than they do a powder. And so we have an option for both patients.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 473.3860629921259147 Td
(So that's, I think, really great that we're able to provide those options to the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(patients. We did do a price increase at the beginning of the year on both products. I think it was) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 416.69314960629913 Td
(the same amount for both in line with what we typically have done in the past. And then on the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 388.3466929133857661 Td
(gross to net question, as we said on the call a couple of months ago, that largely played out in) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 360.0002362204724022 Td
(the fourth quarter. But for the additional, I think it's 1% obligation we have under the Part D) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 331.6537795275589815 Td
(redesign of the IRA that I mentioned in the answer to Jess's question, really no additional) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 303.3073228346455608 Td
(impact there that we observed in Q1.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 260.7876377952754865 Td
(We have Andreas Argyrides with Oppenheimer with the next question. ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(Andreas Argyrides: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
166.0661417322834552 218.2679527559054122 Td
(Let me also extend my congrats on a fantastic quarter here. Martine, you) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(alluded to capital allocation considerations in your opening remarks and I think last time we left) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(James out of the earnings call. So I wanted to make sure he gets the question here. But a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(successful share repurchase that was taking place last year. You have $5 billion in cash. There) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(are a lot of things that are going on in the PAH space from a competitive landscape perspective.) Tj
ET
endstream
endobj
19 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 20 0 R
>>
endobj
20 0 obj
<<
/Length 4001
>>
stream
0.5670000000000001 w
0 G
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(Andreas Argyrides: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
166.0661417322834552 771.0238582677164914 Td
(How do you consider deploying capital, James, maybe you can elaborate) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(deploying capital either for -- in terms of acquisitions to grow the business that way? Or -- and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(also, what are some of your thoughts around a repurchase going into a pretty significant) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(catalyst from IPF and TETON.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 643.4648031496062686 Td
(Sure. Thanks for the questions, Andreas. I'm going to refer the capital) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 615.1183464566928478 Td
(allocation, the bulk of the capital allocation question to James and just giving him a few) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(seconds here while I respond to one of the questions that you sliced in there about internal) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(R&D and the competitiveness of the PAH space and whatnot. So we do, as mentioned in my) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(introductory remarks, we spend about 50% of cash on various forms of internal R&D as well as) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(SG&A, of course.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 459.2128346456692611 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 459.2128346456692611 Td
(And a big part of that spending is, in fact, allocated to our core) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(competencies in pulmonary hypertension and interstitial lung disease. So in that regard, as you) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(know, we have these registration effort going on in -- with ralinepag and the outcome study as) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(well as a lot of effort going toward pulmonary fibrosis with TETON 1, TETON 2, PPF, plus a lot) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(of efforts that don't necessarily have any visibility because they are still in the lead product --) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(lead-in effort for the product and the preclinical. But we have alternative types of methods of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(dosing and variations on dosing. We have a once-daily Tyvaso dosing in preclinical) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(development.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 218.2679527559054122 Td
(So all of these type of activities are continuing on our part. And as we've) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(seen, since the first competition came in to us with, say, something like the Liquidia generic) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(parenteral, I guess it was like 7 years ago or something. I really had no material effect) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(whatsoever. There was quite a bit of concern about sotatercept. We did try to emphasize the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(fact that all signs were that it was much more complementary than anything else.) Tj
ET
endstream
endobj
21 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 22 0 R
>>
endobj
22 0 obj
<<
/Length 4278
>>
stream
0.5670000000000001 w
0 G
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 771.0238582677164914 Td
(And in fact, in the year of rollout, it has proven to be exactly that, quite) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(complementary. So we are constantly -- at UT, we are just relentless in improving our drugs,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(improving our drug delivery devices, like another example I'll just drop there. Our Remunity) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(device is now virtually used by 100% of the patients. So that's pretty amazing to swap out a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(parenteral delivery device that has had many, many years in the clinic and in patients' hands) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(and in essentially about 24 months or so to a virtually 100% swap out of that device.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 586.7718897637794271 Td
(We're now I'm preparing for yet a further upgrade of that one to what we call) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(Remunity D9. You'll see similar types of evolution in our inhalation devices. And as mentioned,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(some of those developments will also allow us to -- even though I think that our 4 times a day) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(dosing now is the easiest, the simplest, super effective as the data shows, loved by physicians) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(and patients as the data shows. I think even there, you'll be able to see in the next few years) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(that we'll be able to come out with new products that go for even once-a-day dosing.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 402.5199212598424765 Td
(So this is just endemic in the UT culture, what we call approve and then) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(improve, approve and then improve and we're relentless about that. Everybody in the company,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(get something approved, then improve it. Get something approved, then improve it. And that's) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(what we're doing on Tyvaso, too. Well, with that lead in, James, can you answer some of the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(more econometric financial aspects of the capital allocation question?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 246.614409448818833 Td
(James Edgemond: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
162.1661417322834779 246.614409448818833 Td
(Yes. Thank you, Martine. Andreas, thank you for the question and thank you) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(for remembering the last call. As you know, we are committed to allocating capital wisely and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(we spend a lot of time internally talking about it. We want to do it in the best interest of our) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(shareholders. And as you know, the first priority is deploying our internal -- our capital for) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(internal research and development and commercial initiatives.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 90.7088976377951894 Td
(James Edgemond: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
162.1661417322834779 90.7088976377951894 Td
(As Martine just explained, there is a lot of -- and the highest priority around) Tj
ET
endstream
endobj
23 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 24 0 R
>>
endobj
24 0 obj
<<
/Length 4058
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(spending for research and development. And if you look at the P&L this quarter, you'll see) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(there was a milestone payment we made in research and development and outsized --) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(increased R&D kind of outsized for the quarter relative to prior quarters, just as we moved) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(along and push along these initiatives that Martine talked about. And we also spend in our first) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(pillar, a lot of capital on our manufacturing facilities. And as you know, we're building a new) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(DPI manufacturing facility in Research Triangle Park, North Carolina that is well on its way.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(James Edgemond: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
162.1661417322834779 586.7718897637794271 Td
(The second priority and consistent priority that we spend capital on is for) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(our external corporate development. So we look for new opportunities for potential) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(acquisitions, in-license opportunities, et cetera. And as Martine outlined in her opening) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(remarks, over the last 1.5 years or so, we've actually touched on all these priorities or touched) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(on these priorities relative to business and corporate development. So it is an area that's very) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(active and we look for products that are complementary to our product -- existing products and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 416.69314960629913 Td
(platforms and tend to focus on rare diseases, things in cardiovascular and things where there) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 388.3466929133857661 Td
(are corridors have been different.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(James Edgemond: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
162.1661417322834779 345.8270078740156919 Td
(So we want to look for opportunities where we can have a big impact and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(there's little products or competition at this point. And third, we do look, as Martine outlined, to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(return cash to shareholders. And as Martine talked about for 2024, we did the $1 billion share) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(repurchase that was well received. So our capital allocation priorities and kind of waterfall is) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(still the same. But as you can see, we've been very active in allocating capital across all 3 in the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 204.0947244094487587 Td
(recent months and years.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(James Edgemond: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
162.1661417322834779 161.5750393700786844 Td
(So thank you very much for remembering. Thank you for the question. And) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(Martine, I'll turn it back to you.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 90.7088976377951894 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 90.7088976377951894 Td
(Thank you, James. Thanks for such a great 360-degree coverage of that) Tj
ET
endstream
endobj
25 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 26 0 R
>>
endobj
26 0 obj
<<
/Length 3896
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(topic.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 728.5041732283464171 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 728.5041732283464171 Td
(Roger Song with Jefferies has the next question for us. ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(Roger Song: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
133.4661417322834893 685.9844881889763428 Td
(Congrats for the strong quarter. I think, Martine, you mentioned a couple of things) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(related to the competitive landscape for PAH. Maybe just can you just qualitatively comment on) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(the potential growth trajectory this year and next, given we have a couple of emerging) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 600.9451181102361943 Td
(competitor dynamic. If you can kind of understand you don't provide the revenue guidance but) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 572.5986614173227736 Td
(just qualitatively, the revenue growth trajectory for the rest of the year and the next will be) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 544.2522047244094665 Td
(helpful.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 501.7325196850393354 Td
(Of course, Roger, thank you for the question. But I right with you. I'm going) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(to assign that question to Michael because he oversees so many of the core competencies that) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(we have within UT relevant to the growth trajectory question. For a complex disease, like PAH) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 416.69314960629913 Td
(and like ILD. Of course, it's very, very important to have a strong commercialization team, sales) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 388.3466929133857661 Td
(and marketing personnel, so-called specialized sales reps throughout the country.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 345.8270078740156919 Td
(But actually, it's just the foundation. And on top of that, there's like a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(superstructure that extends into global medical affairs and many other core competencies. And) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(all of these, we have regional nurse specialists. Our drugs are complex and require almost) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(always a drug device combination and there has to be training and how to use these things,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(working with the nurses, not to mention the entire payer universe.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 189.9214960629919915 Td
(So all of these things are relevant, Roger. And Mike is like a virtuoso) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(conductor who's got all these different sections of the orchestra, all with the goal of providing a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(growth trajectory for our products that is second to none. And with that lead-in, Mike, can you) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(provide some kind of deeper color on all of that?) Tj
ET
endstream
endobj
27 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 28 0 R
>>
endobj
28 0 obj
<<
/Length 4336
>>
stream
0.5670000000000001 w
0 G
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 771.0238582677164914 Td
(Thanks, Martine and thanks for that introduction. I feel like I just won some) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(kind of award. Yes, I think what we've been saying, I think, for the last couple of years and even) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(as recently as the last call and to Martine's comments on this call is we expect to continue to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(grow revenues at double-digit growth with our existing portfolio heading into this year and next) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(year. And then as I said in my opening remarks, if we have TETON, if that -- if that's positive,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(that gets us into an entirely new market where we have orphan exclusivity.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 586.7718897637794271 Td
(I didn't even touch on ralinepag which we're hoping would be) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(commercialized around the same time frame and give us a best-in-class product within PAH. So) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(despite the fact that it is -- PAH in particular, is becoming an increasingly competitive market,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(we still feel like we're extremely well positioned to grow in PAH. As I've said on prior calls, it's) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(still only about 40% of PAH patients are on any kind of prostacyclin. So I think there's plenty of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(room for us to grow.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 402.5199212598424765 Td
(There's plenty of room for, I mean, even the competitive products within) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(that class. So I think it's still -- prostacyclins, I think, are still woefully underprescribed within) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(PAH. And with all of our efforts and all the teams that Martine mentioned, we're continuing to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(make progress there. It wasn't too long ago that we were saying it was only about 20% of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(patients in PAH were on prostacyclin. But I think through the efforts of our company, other) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(companies, bringing new easier products to market such as Tyvaso DPI, we've been able to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(really expand the utilization of prostacyclins within PAH.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 189.9214960629919915 Td
(And then over in PH-ILD, obviously, it's still -- I still feel like we're just) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(scratching the surface in terms of what the potential is there. I think with the expansion that we) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(rolled out last year, I think we -- the team has done an amazing job in increasing our prescriber) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(base as well as the depth of ILD physicians prescribing Tyvaso for pulmonary hypertension) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 76.5356692913385359 Td
(associated with ILD. I expect that to continue as we move into the balance of this year and even) Tj
ET
endstream
endobj
29 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 30 0 R
>>
endobj
30 0 obj
<<
/Length 4061
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(heading into next year and beyond. So we -- I think we still have a lot of opportunity there.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 728.5041732283464171 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 728.5041732283464171 Td
(So we remain very confident that we're going to meet these expectations of) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 700.15771653543311 Td
(continuing to grow revenues at a double-digit clip with our existing portfolio.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 657.6380314960629221 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 657.6380314960629221 Td
(Thank you so much, Mike. Operator, we're actually at the bottom of the hour) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 629.291574803149615 Td
(but we'll take one last question.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 586.7718897637794271 Td
(We have our next question from Ash Verma with UBS. ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 544.2522047244094665 Td
(Ash Verma: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
128.1661417322834779 544.2522047244094665 Td
(Congrats on the quarter. I have 2 questions. Just can you give us a sense of how) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 515.9057480314959321 Td
(much patient adds there have been in the last few quarters for Tyvaso? Is it more in line with) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 487.559291338582625 Td
(the roughly 500-ish that you have had historically or more or less? Just wanted to understand) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 459.2128346456692611 Td
(like the volume growth dynamic for PAH and PH-ILD. And then secondly, for Insmed's) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 430.8663779527558404 Td
(upcoming data on TPIP, just what are you expecting this trial can show?) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 388.3466929133857661 Td
(Ash Verma: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
128.1661417322834779 388.3466929133857661 Td
(And how do you think Tyvaso is competitive position against TPIP? ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 345.8270078740156919 Td
(Okay. Mike, do you want to continue your role on that same topic? ) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 303.3073228346455608 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 303.3073228346455608 Td
(Sure. Yes. I think with -- I think your first question was around patient adds) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 274.9608661417322537 Td
(for Tyvaso. Is that right? So yes, so going back about a year, 1.5 years, we really kind of moved) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 246.614409448818833 Td
(away from the patient add metric due to, I think, just competitive confidentiality reasons. I think) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 218.2679527559054122 Td
(what we said about 1.5 years ago is if you look at the revenue, we've gotten to a point where I) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(think the revenues are tracking pretty well with underlying demand.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 147.4018110236219172 Td
(Michael Benkowitz: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
165.5661417322834836 147.4018110236219172 Td
(And so I think you can kind of look at how the revenues are trending and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 119.0553543307086102 Td
(really get a good sense of what's happening at the underlying demand level. In terms of the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 90.7088976377951894 Td
(Insmed product, we'll see here in a few weeks when they unwind. And so it's hard for me to) Tj
ET
endstream
endobj
31 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 32 0 R
>>
endobj
32 0 obj
<<
/Length 4268
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(sort of speculate on what the impact is going to be relative to Tyvaso without actually seeing) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 742.6774015748030706 Td
(any data but I think we're all going to find out here pretty quick. And then as Martine said in her) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 714.3309448818897636 Td
(answer to a prior question, we have some things that we're looking at in the preclinical setting) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 685.9844881889763428 Td
(and in our pipeline to potentially bring a once-daily inhaled product to market.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 643.4648031496062686 Td
(Yes. Thank you, Mike and thank you, Ash. I'm very skeptical that just copying) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 615.1183464566928478 Td
(treprostinil in a kind of a once-daily formulation is going to really provide comparably effective) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 586.7718897637794271 Td
(control of pulmonary hypertension. However, as Mike and I referred to earlier, we do have a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 558.42543307086612 Td
(once-daily NCE in our early development and the nature of our clinical development team and) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 530.0789763779526993 Td
(process as such that, that can actually move very, very rapidly from preclinical to registration) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 501.7325196850393354 Td
(phase. So not that I think it's necessary but I think all of you know that another big mantra at) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 473.3860629921259147 Td
(United Therapeutics is multiple shots on goal. That's why we have so many products for) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 445.0396062992125508 Td
(pulmonary hypertension.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 402.5199212598424765 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 402.5199212598424765 Td
(As you saw from the data today, all of them are growing. I mean that's super,) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 374.1734645669290558 Td
(super cool, oral, parenteral, inhaled, nebulized DPI. I mean it's just like across the board. So we) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 345.8270078740156919 Td
(are constantly developing new products. And finally, I have not seen anything in -- since the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 317.480551181102328 Td
(company has begun developing products where some new one comes in and kind of steals the) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 289.1340944881889072 Td
(market. It actually has never happened. And the reason why is that when a product -- when a) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 260.7876377952754865 Td
(patient who has a life-threatening illness, is well managed on the medicine as the patients are) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 232.4411811023621794 Td
(well managed on United Therapeutics medicines in overwhelming numbers.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 189.9214960629919915 Td
(Martine Rothblatt: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
158.8661417322834666 189.9214960629919915 Td
(It is a very fraught and cautious and slow process to move those patients to) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 161.5750393700786844 Td
(some like [indiscernible] on the block that has not really been well proven in the clinic. And) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 133.2285826771652637 Td
(these are the reasons, the core reasons why Mike and I and the rest of the team can be so) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 104.882125984251843 Td
(confident that United Therapeutics will continue to deliver the type of double-digit revenue) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 76.5356692913385359 Td
(growth year after year, the kind of record revenue growth that I reported in my introductory) Tj
ET
endstream
endobj
33 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 34 0 R
>>
endobj
34 0 obj
<<
/Length 916
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 771.0238582677164914 Td
(remarks for many years to come. Operator, you can wrap up the call now.) Tj
ET
BT
/F2 10 Tf
11.5 TL
0 g
70.8661417322834666 728.5041732283464171 Td
(Operator: ) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
119.0661417322834694 728.5041732283464171 Td
(Certainly. Thank you. Thank you for participating in today's United Therapeutics) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 700.15771653543311 Td
(Corporation earnings webcast. A rebroadcast of this webcast will be available for replay for 1) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 671.8112598425196893 Td
(week by visiting the Events and Presentations section of the United Therapeutics Investor) Tj
ET
BT
/F1 10 Tf
11.5 TL
0 g
70.8661417322834666 643.4648031496062686 Td
(Relations website at ir.unither.com. That is ir.unither.com. [Call ends abruptly]) Tj
ET
endstream
endobj
1 0 obj
<</Type /Pages
/Kids [3 0 R 5 0 R 7 0 R 9 0 R 11 0 R 13 0 R 15 0 R 17 0 R 19 0 R 21 0 R 23 0 R 25 0 R 27 0 R 29 0 R 31 0 R 33 0 R ]
/Count 16
>>
endobj
35 0 obj
<<
/Type /Font
/BaseFont /Helvetica
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
36 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
37 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
38 0 obj
<<
/Type /Font
/BaseFont /Helvetica-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
39 0 obj
<<
/Type /Font
/BaseFont /Courier
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
40 0 obj
<<
/Type /Font
/BaseFont /Courier-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
41 0 obj
<<
/Type /Font
/BaseFont /Courier-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
42 0 obj
<<
/Type /Font
/BaseFont /Courier-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
43 0 obj
<<
/Type /Font
/BaseFont /Times-Roman
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
44 0 obj
<<
/Type /Font
/BaseFont /Times-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
45 0 obj
<<
/Type /Font
/BaseFont /Times-Italic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
46 0 obj
<<
/Type /Font
/BaseFont /Times-BoldItalic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
47 0 obj
<<
/Type /Font
/BaseFont /ZapfDingbats
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
48 0 obj
<<
/Type /Font
/BaseFont /Symbol
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
2 0 obj
<<
/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]
/Font <<
/F1 35 0 R
/F2 36 0 R
/F3 37 0 R
/F4 38 0 R
/F5 39 0 R
/F6 40 0 R
/F7 41 0 R
/F8 42 0 R
/F9 43 0 R
/F10 44 0 R
/F11 45 0 R
/F12 46 0 R
/F13 47 0 R
/F14 48 0 R
>>
/XObject <<
>>
>>
endobj
49 0 obj
<<
/Producer (jsPDF 2.5.2)
/CreationDate (D:20250527012022-06'00')
>>
endobj
50 0 obj
<<
/Type /Catalog
/Pages 1 0 R
/OpenAction [3 0 R /FitH null]
/PageLayout /OneColumn
>>
endobj
xref
0 51
0000000000 65535 f 
0000064878 00000 n 
0000066803 00000 n 
0000000015 00000 n 
0000000152 00000 n 
0000004214 00000 n 
0000004351 00000 n 
0000008433 00000 n 
0000008570 00000 n 
0000012769 00000 n 
0000012907 00000 n 
0000016913 00000 n 
0000017052 00000 n 
0000020899 00000 n 
0000021038 00000 n 
0000025183 00000 n 
0000025322 00000 n 
0000029319 00000 n 
0000029458 00000 n 
0000033529 00000 n 
0000033668 00000 n 
0000037722 00000 n 
0000037861 00000 n 
0000042192 00000 n 
0000042331 00000 n 
0000046442 00000 n 
0000046581 00000 n 
0000050530 00000 n 
0000050669 00000 n 
0000055058 00000 n 
0000055197 00000 n 
0000059311 00000 n 
0000059450 00000 n 
0000063771 00000 n 
0000063910 00000 n 
0000065038 00000 n 
0000065164 00000 n 
0000065295 00000 n 
0000065429 00000 n 
0000065567 00000 n 
0000065691 00000 n 
0000065820 00000 n 
0000065952 00000 n 
0000066088 00000 n 
0000066216 00000 n 
0000066343 00000 n 
0000066472 00000 n 
0000066605 00000 n 
0000066707 00000 n 
0000067056 00000 n 
0000067142 00000 n 
trailer
<<
/Size 51
/Root 50 0 R
/Info 49 0 R
/ID [ <BF961A83D6B781503796B5379D599D85> <BF961A83D6B781503796B5379D599D85> ]
>>
startxref
67246
%%EOF